Compare prices and buy hMG from 2 research peptide vendors - also called suppliers or sources. Updated daily.
Human menopausal gonadotropin (menotropins, CAS 61489-71-2), a mixture of the pituitary glycoprotein hormones FSH and LH extracted and purified from the urine of postmenopausal women, and not a synthetic peptide. FSH acts at its receptor on ovarian granulosa cells to drive follicular growth, and the LH activity acts at the LH/hCG receptor, where the product's UK label says added hCG can be the main contributor. Its one marketed US product, Ferring's Menopur, is licensed as a biological product for multiple follicular development in assisted reproduction. It is catalogued here because vendors sell it beside research peptides, and it is sold in International Units, so it has no price-per-milligram figure.
For research purposes only. Not medical advice.
Human menopausal gonadotropin (hMG), nonproprietary name menotropins, is a preparation of the two pituitary gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH), extracted from the urine of postmenopausal women. It is not a synthetic peptide. The Menopur label describes both hormones as acidic, water-soluble glycoproteins, the same hormone class as hCG, and FDA's substance registry (GSRS) records menotropins as a mixture of LH and FSH.
The form in current US use is highly purified. Menopur's label says its urinary extract has undergone additional steps for purification, and it also states that hCG is detected in the product.
Menopur's label summarizes the result as follicular growth and maturation in women without primary ovarian failure, and adds that ovulation does not follow on its own: once follicles have matured, hCG must be given to induce it.
On the LH side, Menopur's UK label says hCG obtained from the urine of pregnant women may be added to reach the required LH activity and can serve as its main contributor. Set beside its neighbours, hMG supplies FSH and LH-receptor activity together, recombinant FSH supplies FSH alone, and hCG acts mainly at the LH/hCG receptor.
Like hCG, hMG acts on the gonad rather than the pituitary, so its action does not depend on a working pituitary. In the trial behind Menopur's US label, every participant began stimulation after pituitary suppression with a GnRH agonist. That places it below gonadorelin and kisspeptin-10 in the reproductive axis set out on the hormonal category page.
Menopur's US label rests its efficacy on one randomized, open-label, multicenter trial in Europe and Israel, in women undergoing IVF or IVF with intracytoplasmic sperm injection. Continuing pregnancy, defined as a gestational sac with fetal heartbeat at least 10 weeks after embryo transfer, occurred in 23% of the 373 women randomized to Menopur, which the label calls non-inferior to recombinant human FSH in the intent-to-treat analysis.
Two later randomized trials compared highly purified hMG with recombinant FSH.
A multinational, assessor-blind trial reported by Andersen and colleagues (Human Reproduction, 2006) randomized 731 women undergoing IVF to highly purified hMG or follitropin alfa after a long GnRH agonist protocol. Ongoing pregnancy per cycle, its primary end-point, was 27% with hMG and 22% with follitropin alfa (odds ratio 1.25, 95% CI 0.89 to 1.75), and the authors concluded that non-inferiority was established and superiority was not.
MEGASET (Devroey and colleagues, Fertility and Sterility, 2012, NCT00884221), sponsored by Menopur's maker Ferring, randomized 749 women at 25 centers in seven countries to the same comparison in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Ongoing pregnancy after the fresh cycle was 29% against 27% in the intention-to-treat population and 30% against 27% per protocol, again establishing non-inferiority. Counting frozen transfers started within a year, the cumulative live birth rate was 40% against 38%.
hMG holds a current US approval, so its status is not decided by the 503A bulks-list and Category 2 process that governs most research peptides.
FDA's Purple Book (October 2026 data) lists Menopur as the only menotropins product still marketed. Pergonal and Repronex are discontinued but remain licensed, and Humegon's license was voluntarily revoked.
All four were approved as new drug applications. On March 23, 2020, a provision of the Biologics Price Competition and Innovation Act deemed them biologics licenses, and FDA's list of transitioned applications names each one. The hCG hub covers what that transition means for compounding.
Vendors list it as hMG, HMG, menotropins or human menopausal gonadotropin. Like hCG's, its potency is defined by biological activity rather than mass. Menopur's label assays FSH by ovarian weight gain in female rats and LH by seminal vesicle weight gain in male rats, both standardized against the WHO Fourth International Standard for Urinary FSH and Urinary LH. Each Menopur vial therefore carries two figures, 75 International Units of FSH activity and 75 of LH activity.
Human menopausal gonadotropin (menotropins) is a mixture of two pituitary hormones, FSH and LH, extracted from the urine of postmenopausal women. Human chorionic gonadotropin is a single placental hormone that acts mainly at the LH/hCG receptor. hMG therefore adds FSH activity, which drives follicular growth through the FSH receptor on ovarian granulosa cells. The two overlap on the LH side. The US Menopur label states that hCG is detected in the product, and its UK label says hCG from the urine of pregnant women may be added to reach the required LH activity and can be its main contributor.
Menopur, Ferring Pharmaceuticals' menotropins for injection, was approved by FDA on October 29, 2004, for the development of multiple follicles and pregnancy in ovulatory women as part of an assisted reproductive technology cycle. FDA's Purple Book (October 2026 data) lists it as the only menotropins product still marketed in the US. The earlier products Pergonal (Serono, 1975), Humegon (Organon, 1994) and Repronex (Ferring, 1999) are discontinued. On March 23, 2020, FDA deemed all four approved applications to be biologics licenses.
Two randomized trials found highly purified hMG non-inferior to recombinant FSH on ongoing pregnancy. In a multinational trial reported in Human Reproduction in 2006, 731 women undergoing IVF after a long GnRH agonist protocol had ongoing pregnancy rates per cycle of 27% with hMG and 22% with follitropin alfa, and the authors established non-inferiority but could not conclude superiority. In MEGASET (Fertility and Sterility, 2012), sponsored by Menopur's maker Ferring, 749 women in a GnRH antagonist cycle with single-blastocyst transfer had ongoing pregnancy rates of 29% and 27% in the intention-to-treat population.
Not in the sense the rest of this catalog uses the word. hMG is a mixture of two glycoprotein hormones, FSH and LH, extracted and purified from the urine of postmenopausal women rather than synthesized, and FDA's substance registry records menotropins as a mixture of LH and FSH. Its potency is defined by bioassay in International Units, not by mass. It is listed among research peptides because vendors sell it beside them.
hMG is sold by 2 research peptide vendors indexed on PeptideScouter, with 3 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
All 2 indexed research peptide vendors currently have hMG in stock. Stock state is refreshed daily from each vendor's catalog.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 2 vendors listing hMG publish a PeptideScouter code, worth 10% off. These listings do not carry a comparable per-milligram price, so code availability is shown without a normalized effective price. Each vendor's code is shown beside its price in the table above.
2 research peptide vendors currently list hMG on PeptideScouter. We track 3 listings across size and kit variants.
hMG's CAS Registry Number is 61489-71-2. It is also sold as HMG, Menotropins, Human Menopausal Gonadotropin.
